AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 288: H729-H736, 2005. First published October 7, 2004; doi:10.1152/ajpheart.00388.2004
0363-6135/05 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/2/H729    most recent
00388.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, H.
Right arrow Articles by Fink, G. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, H.
Right arrow Articles by Fink, G. D.

Endothelin in the splanchnic vascular bed of DOCA-salt hypertensive rats

Hong Wang, Alex F. Chen, Stephanie W. Watts, James J. Galligan, and Gregory D. Fink

Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan

Submitted 27 April 2004 ; accepted in final form 6 October 2004


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Vascular capacitance is reduced by endothelin-1 (ET-1) in deoxycorticosterone (DOCA)-salt hypertensive rats. This may contribute to hypertension development. Because the splanchnic blood vessels (especially veins) are important in determining vascular capacitance, we tested the hypothesis that ET-1 levels in the splanchnic vasculature are elevated in hypertensive DOCA-salt compared with normotensive rats. Tissue ET-1 content was measured by ELISA in aorta, vena cava, superior mesenteric artery and vein, and small mesenteric arteries and veins from normotensive sham-operated (sham) and 4-wk DOCA-salt rats. We also determined ET-1 concentration in aortic and portal venous blood (draining the nonhepatic splanchnic organs) in anesthetized and conscious sham and DOCA-salt rats before and after acute blockade of ETB receptor-mediated plasma clearance of ET-1. Results showed a higher ET-1 content in veins than in arteries of similar size. However, ET-1 content was similar in vessels from sham and DOCA-salt rats, except in aorta and superior mesenteric artery, where ET-1 content was greater in DOCA-salt rats. ET-1 concentration was significantly higher in portal venous than in aortic blood, indicating net nonhepatic splanchnic release (nNHSR) of ET-1. However, nNHSR of ET-1 was similar in sham and DOCA-salt rats. Although nNHSR of ET-1 increased significantly after ETB receptor blockade in sham rats, it was completely unchanged in DOCA-salt rats. These data suggest that, despite the absence of ETB receptor-mediated plasma clearance of ET-1, neither the venous peptide content nor the net release of ET-1 is increased in the splanchnic vasculature of DOCA-salt rats. These results argue against the hypothesis that increased venomotor tone in DOCA-salt hypertension is caused by increased ET-1 concentration around splanchnic venous smooth muscle cells.

endothelin-1; splanchnic vasculature; vascular capacitance; veins; deoxycorticosterone

THE ENDOTHELIUM REGULATES local vascular tone through release of vasodilator and vasoconstrictor substances (21). Endothelin-1 (ET-1), synthesized by endothelial cells, is a very potent vasoconstrictor. It has been implicated in the pathogenesis of hypertension in humans and experimental animals (4, 7, 17, 18). ET-1 has an especially prominent role in salt-sensitive forms of hypertension, such as deoxycorticosterone (DOCA)-salt hypertension (31). One important effect of ET-1 in DOCA-salt hypertension is to increase total peripheral resistance by contracting arteries and arterioles (44). Most studies have shown, however, that arterial plasma levels of ET-1 are not increased in DOCA-salt rats (25, 26, 32, 36, 40). Nonetheless, prepro-ET-1 mRNA expression and immunoreactive ET-1 content of aorta and mesenteric arteries are increased in DOCA-salt rats (8, 19, 20, 32), suggesting that one mechanism of ET-1-induced arterial constriction in hypertension is increased level of the peptide around arterial smooth muscle. A caveat to that conclusion is raised by findings that contractions to ET-1 are significantly reduced in arteries of DOCA-salt compared with sham rats (15). Thus increased local production of ET-1 by arteries may be countered by decreased arterial responsiveness, and it remains unclear how ET-1 increases vascular resistance in DOCA-salt hypertension.

Hypertensive humans and experimental animals also exhibit decreased systemic vascular capacitance (28, 30). This is primarily the result of changes in the structure or vasoconstrictor activity of extrathoracic veins, especially those in the splanchnic bed (30). Reduced vascular capacitance contributes to the hemodynamics of hypertension by contributing, along with blood volume, to maintenance of "effective blood volume," a critical determinant of venous return of blood to the heart and, thus, cardiac output (30). We recently reported evidence for increased venoconstriction in conscious DOCA-salt rats using repeated measurements of blood volume and mean circulatory filling pressure (MCFP), an in vivo index of venous smooth muscle contractile activity (12). Endogenous ET-1 appears at least partly responsible for that augmented venoconstriction, because we also showed that ET receptor antagonists lower MCFP in hypertensive DOCA-salt, but not normotensive, rats (16).

As with vascular resistance, two mechanisms could explain increased ET-1-mediated venoconstriction: 1) higher levels of the peptide around venous smooth muscle cells and/or 2) enhanced responsiveness of venous smooth muscle to ET-1. We previously showed that vena cava and small mesenteric veins from DOCA-salt rats do not exhibit increased reactivity to ET-1 in vitro (15, 41). Therefore, it was logical to conclude that higher ET-1-mediated venomotor tone in DOCA-salt rats is caused by increased ET-1 concentrations around venous smooth muscle. Measurement of prepro-ET-1 gene expression, as an index of ET-1 synthesis, in small veins, however, revealed no differences between sham and DOCA-salt rats (15). That finding does not support the hypothesis that increased venomotor activity in DOCA-salt rats is caused by local overproduction of ET-1 by veins.

Veins in DOCA-salt rats could be exposed to higher concentrations of ET-1 by mechanisms other than increased venous endothelial cell synthesis. For example, increased production and release into blood of ET-1 from upstream arterial endothelial cells could affect venous smooth muscle cell activity directly or provide "excess" ET-1 to be taken up into venous endothelial cells for subsequent release. To test these possibilities, we made two kinds of measurements to estimate ET-1 concentrations in the biophase around venous smooth muscle cells: 1) total vascular ET-1 content and 2) venous plasma ET-1 concentration. Measurements were made in the splanchnic vascular bed, because it represents the most important capacitance bed in the circulation. We also estimated net nonhepatic splanchnic release (nNHSR) of ET-1 by determining the difference between ET-1 concentrations in inflowing arterial and outflowing portal venous blood. The liver was excluded from these experiments because of the difficulty of sampling blood from the hepatic venous drainage in the rat. This also prevents the interference of hepatic ET-1 extraction with the measurement of splanchnic release.

Initial experiments were performed in anesthetized rats. Additional studies were performed in conscious rats, because anesthesia and acute surgery can affect hormone synthesis and release.

Plasma ET-1 level is determined by a combination of factors, including production rate, metabolism, and clearance. Previous studies indicate that clearance by endothelial ETB receptors is the most important mechanism for removing ET-1 from blood (3, 29, 34, 35). To test the possibility that a functional alteration in ETB receptors might affect the venous plasma ET-1 concentration in DOCA-salt hypertension, we measured the portal venous-aortic plasma ET-1 difference after selective ETB receptor blockade in anesthetized and conscious rats.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Animals. The protocols were approved by the Michigan State University Committee on Animal Use and Care. Male Sprague-Dawley rats (Charles River Laboratories, Portage, MI; 175–225 g body wt) were housed two to three per cage under conditions of constant humidity and temperature and subjected to 12:12-h light-dark cycles. After 2–3 days of habituation, rats were uninephrectomized, DOCA pellets (200 mg/kg; Sigma) were implanted subcutaneously, and rats were offered drinking water that contained 1% NaCl and 0.2% KCl. Sham-operated rats were uninephrectomized and drank tap water. All rats were fed standard pelleted rat chow (8640 Rodent Diet, Harlan/Teklad, Madison, WI). At 3 wk after surgery, systolic blood pressure was measured using the tail-cuff method (pneumatic transducer, Narco). Rats with a tail-cuff blood pressure of >150 mmHg were considered hypertensive.

Vascular ET-1 content measurement. At ~4 wk after DOCA implantation or sham surgery, rats were euthanized by pentobarbital sodium overdose (100 mg/kg ip; Sigma), and segments of thoracic aorta, thoracic vena cava, and abdominal vena cava were removed and dissected free of fat. The complete mesenteric vascular bed was removed and placed in a petri dish full of ice-cold Krebs solution. The small intestine was stretched gently and pinned flat. Superior mesenteric artery and vein and small mesenteric arteries and veins (150–250 µm diameter) were dissected free of fat and collected separately. The tissues were snap frozen in liquid nitrogen and stored at –80°C until extraction of ET-1 was performed. On the day of extraction, tissues were homogenized with a Polytron in 1 ml of 1 M acetic acid containing 10 µg/ml pepstatin A (ICN Pharmaceuticals, Costa Mesa, CA) and immediately heated to 100°C for 10 min. The homogenate was chilled and then centrifuged at 14,000 g for 30 min at 4°C. The supernatant was dried in a Speed-Vac and then reconstituted in 300 µl of calibrator diluent (R & D Systems, Minneapolis, MN). The reconstituted sample was stored at –80°C until measurement of ET-1 was performed.

Catheterization and sampling of blood. At ~3.5 wk after DOCA implantation or sham surgery, vascular catheters were placed in each rat. Anesthesia was produced with pentobarbital sodium (30–50 mg/kg ip), and atropine (0.2 mg/kg ip; Sigma) was administered to decrease bronchial secretion. A silicone rubber catheter was inserted into the abdominal aorta via a femoral artery for blood sampling and blood pressure recording. Through a midline laparotomy, another catheter was inserted into the portal vein via a small branch of the portal vein for venous blood sampling. Because ET-1 concentration in portal venous blood is derived in part from inflowing arterial blood and in part from peptide released from splanchnic tissues (mainly endothelial cells) themselves, the difference ("step-up") between arterial and portal venous plasma ET-1 concentrations was used as an index of nNHSR of ET-1. We excluded liver from the experiment to prevent the interference of hepatic ET-1 extraction with measurement of splanchnic release by portal venous, instead of hepatic venous, sampling. A third catheter was placed into the abdominal vena cava through a femoral vein for drug administration. In the anesthetized group, rats were allowed to recover from surgery on a heated pad for 30 min before blood sampling (see below). A-192621 (12 mg/kg iv; Abbott Laboratories), a selective ETB receptor antagonist (42), was then given, and blood samples were collected again 30 min later. It has been shown by previous studies in our laboratory (16) that this dose of A-192621 is effective at blocking ETB receptors and causes a significant increase in mean arterial pressure (MAP) in DOCA-salt rats. The increase reaches maximum at 30 min after A-192621 administration.

An additional experiment was performed in anesthetized rats to test the potential role of ETA receptors in the plasma clearance and nNHSR of ET-1. A-182086 (12 mg/kg iv; Abbott Laboratories), a mixed ETA-ETB receptor antagonist, was given to rats 30 min after recovery from catheterization as described above. Aortic and portal venous blood samples were collected before and 1 h after drug treatment. The dose of A-182086 was shown to be efficacious in preliminary studies in which antagonist was tested against acute pressor actions of ET-1 (data not shown). Published studies also indicate that this dose is effective in blocking both receptor subtypes in rats (42). The nNHSR of ET-1 after A-182086 treatment was compared with that after treatment with the selective ETB receptor antagonist A-192621. The difference was used as an index of the amount of ET-1 bound to ETA receptors in the splanchnic vasculature.

In rats to be studied while conscious, the ends of all three catheters were tunneled subcutaneously to the head, where they exited the rat inside a stainless steel spring secured to the skull with jeweler’s screws and cyanoacrylate glue. Injections of enrofloxacin (5 mg/kg iv; Bayer) were given for bacterial prophylaxis. Rats were allowed to recover consciousness on a heated pad under constant observation. They were then placed in stainless steel metabolism cages under loose tethering, allowing continuous access to all catheters without handling or otherwise disturbing the rat. Enrofloxacin (5 mg/kg iv) was administered to all rats for 3 days after surgery. Vascular catheters were filled with heparin saline solutions when not in use and flushed daily. Experiments were started after ≥4 days of surgical recovery, inasmuch as previous work in our laboratory indicated that normal food and saline intake in DOCA-salt rats typically did not recover to presurgery level for 4 days. Blood samples (with and without A-192621 treatment) were taken with ≥1 day separating experiments. In anesthetized and conscious groups, 0.5-ml blood samples were collected simultaneously from arterial and portal venous catheters into ice-chilled plastic syringes and transferred to ice-chilled plastic tubes containing EDTA. Blood samples were centrifuged at 10,000 g for 5 min at 4°C. Plasma was separated and stored at –80°C until assayed.

Hemodynamic measurements. Arterial pressure of anesthetized rats was determined by connecting the arterial catheter to a transducer linked to a pen chart recorder (Kent Scientific, Torrington, CT). In the conscious group, arterial pressure was determined by connecting the arterial catheter to a low-volume-displacement pressure transducer (model TXD-300, Micro-Med, Louisville, KY) linked to a digital pressure monitor (model BPA-200, Micro-Med), which derives systolic, mean, and diastolic pressures and heart rate every 0.5 s (sampling rate = 1,000 Hz). All values were averaged minute-by-minute and saved using a computerized data acquisition system (model DMSI-200/4, Micro-Med).

Measurement of ET-1. Vascular ET-1 content and plasma ET-1 concentration were measured by quantitative sandwich enzyme immunoassay using the ET-1 QuantiGlo chemiluminescent assay kit (R & D Systems, Minneapolis, MN). The minimum detectable concentration of ET-1 is ~0.16 pg/ml. Some cross-reactivity and interference were observed with human Big ET-2, porcine Big ET-39, human Big ET-38, bovine Big ET-39, rat Big ET-39, sarafotoxin, human ET-3, and human ET-2. Inter- and intra-assay coefficients of variation are 7.1 and 2.1%, respectively.

Data analysis. Values are means ± SE. Comparisons of vascular ET-1 content and plasma ET-1 concentration between DOCA-salt and sham rats were made using Student’s t-tests for paired or independent samples where appropriate. Bonferroni’s correction for multiple comparisons was applied where appropriate. Differences were considered significant at P < 0.05.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
MAP. Average MAP recorded from conscious, freely moving DOCA-salt rats was significantly greater than the average value recorded from conscious sham rats. In anesthetized animals, the average MAP recorded from DOCA-salt rats was the same as that recorded from sham rats. The average MAP was significantly greater in conscious than in anesthetized DOCA-salt rats (Fig. 1).



View larger version (13K):
[in this window]
[in a new window]
  		Fig. 1. Mean arterial pressure of anesthetized sham and deoxycorticosterone (DOCA)-salt hypertensive rats. Values are means; error bars represent SE. *P < 0.05 vs. conscious sham. #P < 0.05 vs. anesthetized DOCA.

 
Vascular ET-1 content. ET-1 content (normalized by tissue wet weight) in thoracic aorta, thoracic vena cava, abdominal vena cava, superior mesenteric artery and vein, and small mesenteric arteries and veins from sham and DOCA-salt rats was measured using ELISA after acid extraction (Fig. 2). On the basis of tissue weight, ET-1 content was greater in veins than in arteries of similar size. ET-1 content was higher in small than in larger vessels. ET-1 content was significantly higher in aorta and superior mesenteric artery from DOCA-salt than from sham rats. There was no difference in ET-1 content in other vessels between sham and DOCA-salt rats.



View larger version (21K):
[in this window]
[in a new window]
  		Fig. 2. Endothelin-1 (ET-1) content in blood vessels from sham and DOCA-salt rats. Values are means; error bars represent SE. *P < 0.05 vs. sham.

 
Plasma concentrations of ET-1. Plasma ET-1 concentration was significantly higher in portal vein than in aorta in anesthetized sham and DOCA-salt rats, indicating nNHSR of ET-1. However, there was no difference in portal venous plasma ET-1 level between sham and DOCA-salt rats or in aortic plasma ET-1 level between the two groups (Fig. 3A).



View larger version (15K):
[in this window]
[in a new window]
  		Fig. 3. Aortic and portal venous plasma ET-1 concentrations in anesthetized (A) and conscious (B) sham and DOCA-salt rats. Values are means; error bars represent SE. *P < 0.05 vs. aorta. #P < 0.05 vs. anesthetized rats.

 
Plasma ET-1 concentration also was significantly higher in portal vein than in aorta in conscious sham and DOCA-salt rats. However, there was no difference in portal venous plasma ET-1 level between conscious sham and DOCA-salt rats or in aortic plasma ET-1 levels between the two groups (Fig. 3B).

The aortic and portal venous plasma ET-1 concentrations were significantly lower in conscious than in anesthetized sham rats. The portal venous plasma ET-1 concentration was significantly lower in conscious than in anesthetized DOCA-salt rats (Fig. 3). The aortic plasma ET-1 concentration was lower in conscious than in anesthetized DOCA-salt rats, but the difference was not quite significant (P = 0.066).

Total ETB receptor-mediated plasma clearance of ET-1. Administration of the ETB receptor antagonist A-192621 caused a significant increase in MAP in anesthetized DOCA-salt and sham rats (Fig. 4A). A-192621 also caused a significant increase in MAP in conscious sham, but not conscious DOCA-salt, rats (Fig. 4B).



View larger version (17K):
[in this window]
[in a new window]
  		Fig. 4. Mean arterial pressure before and after A-192621 treatment in anesthetized (A) and conscious (B) sham and DOCA-salt rats. Values are means; error bars represent SE. *P < 0.05 vs. control. #P < 0.05 vs. sham.

 
A-192621 caused a significant increase in aortic plasma ET-1 concentration in anesthetized (Fig. 5A) and conscious (Fig. 5B) sham and DOCA-salt rats. There was no difference in aortic plasma ET-1 concentrations between sham and DOCA-salt rats after A-192621 treatment under anesthesia or in the conscious state. The change in aortic plasma levels of ET-1 before and after treatment also was not different between sham and DOCA-salt rats.



View larger version (17K):
[in this window]
[in a new window]
  		Fig. 5. Aortic plasma ET-1 concentration before and after drug treatment in anesthetized (A) and conscious (B) sham and DOCA-salt rats. Values are means; error bars represent SE. *P < 0.05 vs. control. #P < 0.05 vs. anesthetized rats.

 
At 30 min after A-192621 treatment, portal venous plasma ET-1 concentration was significantly and similarly increased in anesthetized and conscious sham and DOCA-salt rats (Fig. 6).



View larger version (18K):
[in this window]
[in a new window]
  		Fig. 6. Portal venous plasma ET-1 concentration before and after drug treatment in anesthetized (A) and conscious (B) sham and DOCA-salt rats. Values are means; error bars represent SE. *P < 0.05 vs. control. #P < 0.05 vs. anesthetized rats.

 
ETB receptor-mediated plasma clearance of ET-1 in nonhepatic splanchnic vasculature. The nNHSR of ET-1 was the same in anesthetized sham and DOCA-salt rats. After A-192621 treatment, there was a significant increase in nNHSR of ET-1 in sham, but not DOCA-salt, rats (Fig. 7A).



View larger version (16K):
[in this window]
[in a new window]
  		Fig. 7. Net nonhepatic splanchnic release of ET-1 before and after drug treatment in anesthetized (A) and conscious (B) sham and DOCA-salt rats. Values are means; error bars represent SE. *P < 0.05 vs. control. #P < 0.05 vs. anesthetized rats.

 
In conscious animals, nNHSR of ET-1 also was the same in sham and DOCA-salt rats. After ETB receptor antagonist treatment, nNHSR of ET-1 was significantly increased in sham rats but remained unchanged in DOCA-salt rats (Fig. 7B). The basal nNHSR of ET-1 was significantly lower in conscious than in anesthetized sham rats. The nNHSR of ET-1 was lower in conscious than in anesthetized DOCA-salt rats, but the difference was not significant (P = 0.057).

Potential ETA receptor-mediated plasma clearance of ET-1 in nonhepatic splanchnic vasculature. A-182086 treatment did not cause a significant change in MAP in DOCA-salt or sham rats. A-182086 significantly increased aortic and portal venous plasma ET-1 concentrations in both groups: from 2.3 ± 0.3 to 64.7 ± 5.7 pg/ml in aortic blood and from 3.5 ± 0.3 to 78.0 ± 8.5 pg/ml in portal venous blood of sham rats and from 1.1 ± 0.1 to 46.0 ± 8.7 pg/ml in aortic blood and from 2.1 ± 0.2 to 62.3 ± 8.0 pg/ml in portal venous blood of DOCA-salt rats. The nNHSR of ET-1 of both groups was significantly increased (Fig. 8). By comparing those values with data from A-192621-treated rats, the effect of ETA receptors on nNHSR of ET-1 was estimated. This effect was not significantly different in DOCA-salt and sham rats (14.4 ± 5.6 vs. 8.7 ± 4.6 pg/ml).



View larger version (18K):
[in this window]
[in a new window]
  		Fig. 8. Net nonhepatic splanchnic release of ET-1 before and after drug treatment in anesthetized sham and DOCA-salt rats. Values are means; error bars represent SE. *P < 0.05 vs. control.

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
ET-1 content of mesenteric arteries and veins. Our studies focused on the splanchnic circulation, because the veins of the splanchnic vasculature hold the largest amount of blood within the venous system (~40% of total blood volume), so systemic vascular capacitance depends largely on veins (especially small mesenteric veins) in this region. Structural or neurohumoral changes in these vessels can lead to a reduction in vascular capacitance. This would increase cardiac filling pressure as blood is translocated toward the heart. The resulting elevation of cardiac output could be a factor in the development and maintenance of hypertension.

ET-1 content of blood vessels is determined by local vascular production and reuptake and storage of the peptide. These processes occur predominantly, but not exclusively, in endothelial cells. Total vascular content of ET-1 thus represents a rough index of local concentrations of the peptide available to cause vasoconstriction in vivo. Measurements of splanchnic vascular ET-1 content in this study produced novel findings. 1) On the basis of tissue weight, ET-1 content is higher in veins than in arteries. This may reflect a higher ratio of endothelial cells to other cell types in veins than in arteries or a greater ET-1 synthetic capacity of venous than of arterial endothelial cells. 2) ET-1 content was higher in smaller than in larger vessels. This may reflect the relative amount of endothelial cells in our samples (especially in arteries) but also is consistent with an important role for ET-1 in control of vascular resistance and capacitance, because these physiological functions are mainly served by smaller vessels in the intact circulation. 3) We found that vascular ET-1 content was significantly greater in DOCA-salt rats only in the aorta and superior mesenteric artery, and not in veins of any size. This suggests that production of ET-1 by venous endothelial cells is not increased in DOCA-salt rats and is consistent with our previous finding of unchanged prepro-ET-1 mRNA level in mesenteric veins in DOCA-salt rats (15).

Steady-state vascular content of ET-1, however, may not be an accurate indicator of local formation of ET-1 around venous capacitance vessels, because released ET-1 in vivo is subjected to rapid tissue binding, reuptake, and metabolism. The kinetics of ET-1 disposition are only beginning to be understood (9, 10).

ET-1 level in venous blood and nNHSR of ET-1. We conducted additional experiments designed to evaluate the rate of ET-1 release by the nonhepatic splanchnic vasculature of normotensive and hypertensive DOCA-salt rats in vivo. Although ET-1 release by endothelial cells is reported to be polarized toward vascular smooth muscle (80%) compared with blood (20%), we reasoned that venous blood (portal vein) draining the splanchnic bed (except the liver) would yield a reliable estimate of differences in ET-1 production and release by splanchnic vessels. Because part of portal venous plasma ET-1 is derived from arterial blood entering the splanchnic bed, it was also necessary to measure arterial plasma ET-1 levels. Thus, in analogy to other studies (1, 6), we used the difference between arterial and portal venous ET-1 plasma concentrations as an index of nNHSR of ET-1. Previous studies demonstrated that arterial plasma levels of ET-1 are not increased in DOCA-salt rats. Our results confirmed this finding in anesthetized and conscious DOCA-salt rats (Fig. 3). No studies have been reported on splanchnic venous plasma ET-1 level or nNHSR in this model of hypertension. We hypothesized that portal venous plasma ET-1 concentration and nNHSR of ET-1 would be higher in DOCA-salt than in sham rats. This would indicate that the endothelial cells in the splanchnic vasculature of DOCA-salt rats release more ET-1 in vivo and that venous smooth muscle cells of the splanchnic bed are exposed to higher ET-1 concentrations.

Data reported here show that portal venous plasma ET-1 level is significantly higher than aortic plasma ET-1 level in anesthetized hypertensive DOCA-salt and normotensive sham rats, indicating nNHSR of ET-1 in both groups of animals. However, there was no difference in portal venous plasma ET-1 level or in nNHSR of ET-1 between the two groups. This provides the first in vivo evidence that endothelial cells of the splanchnic vasculature do not produce more ET-1 in DOCA-salt than in sham rats. However, as mentioned above, plasma ET-1 level is determined by a combination of factors, including production rate, metabolism, clearance, and regional blood flow. Blood flows to the stomach and small and large intestines are not affected by DOCA-salt treatment (14, 43), so disparities in regional blood flow are not likely to contribute to our findings. Another mechanism that could influence venous plasma ET-1 level and nNHSR of ET-1 in DOCA-salt rats is altered ETB receptor-mediated uptake activity. For example, enhanced endothelial cell production and release of ET-1 in the splanchnic vasculature of DOCA-salt rats might not be apparent with our in vivo measurements if there is also increased removal of ET-1 from plasma by reuptake into endothelial cells.

ET-1 clearance by ETB receptors. ET-1 is rapidly removed from circulating blood, and current evidence suggests that the ETB receptor is very important for that process. ET-1 binds almost irreversibly to the ETB receptor under physiological conditions (38). Direct transport of ETB receptor-associated ET-1 to lysosomes for degradation may serve as the main mechanism for clearance of plasma ET-1 (2). To determine whether altered endothelial ETB receptor-mediated uptake activity contributes to venous plasma ET-1 level and nNHSR of ET-1, we measured the portal venous plasma ET-1 concentration and portal venous-aortic plasma ET-1 difference in the presence of the selective ETB receptor antagonist A-192621. We found a significant increase in portal venous-aortic plasma ET-1 difference in sham, but not DOCA-salt, rats after acute blockade of ETB receptors. Thus, in sham rats, there is significant clearance of ET-1 from the splanchnic circulation through uptake mediated by ETB receptors. The uptake activity of endothelial ETB receptors in the splanchnic vasculature of DOCA-salt rats, however, was significantly decreased (or even absent). However, the whole body clearance of ET-1 mediated by the ETB receptor (predominantly pulmonary), which is reflected by the aortic plasma ET-1 concentration difference before and after A-192621 treatment, was unchanged in DOCA-salt rats. These novel results reveal a regionally specific defect in ETB receptor-mediated plasma clearance of ET-1 in the splanchnic vasculature of DOCA-salt rats.

Mechanism and impact of reduced ETB-mediated plasma clearance of ET-1. Possible mechanisms underlying the decreased uptake activity of ETB receptor specifically in the splanchnic vasculature of DOCA-salt rats include 1) a decrease in overall endothelial cell function, 2) a decreased density of endothelial ETB receptors, 3) a lower binding affinity of ETB receptors for ET-1, or 4) altered postreceptor ET-1 disposition mechanisms. Available data do not allow a clear distinction between these possibilities, although functional responses of small mesenteric veins to ETB receptor activation did not differ in sham and DOCA-salt rats (15). Previous results indicate that immunoreactive ETB receptor number tends to be higher in vena cava than in aorta, but no difference was found in the vena cava of sham vs. DOCA-salt rats (41). However, that study did not distinguish between endothelial and smooth muscle ETB receptors; these probably differ in their ability to clear ET-1 from the circulation. Possible differences between large and small veins also were not considered. In future studies, we will use immunohistochemistry and binding studies to compare the density of endothelial ETB receptors in the small mesenteric veins of sham and DOCA-salt rats. In any case, the physiological significance of reduced splanchnic ET-1 plasma clearance by ETB receptors is not known; i.e., it is uncertain whether the decreased uptake activity of ETB receptor in the splanchnic vasculature affects the ability of ET-1 to control vascular capacitance in DOCA-salt rats. Further work is required to address that question.

Potential role of ETA receptors in the plasma clearance of ET-1 in the splanchnic vasculature. Binding of ET-1 to ETA receptors on vascular smooth muscle cells may also influence circulating ET-1 level, because in contrast to other hormones, there appears to be a small amount of ET peptide in relation to the concentration of ET receptors (13). Besides, the binding of ET-1 to its receptors is particularly tight, and ET-1 remains bound to ETA receptors, even after their internalization (4). To test the possibility that ETA receptor binding contributes to the nNHSR of ET-1, we compared nNHSR of ET-1 after ETA-and-ETB receptor blockade with that after selective ETB receptor antagonism alone. The difference was used as an index of the amount of ET-1 bound to ETA receptors in the splanchnic vasculature. We found that ETA-and-ETB receptor blockade caused a significant increase in aortic and portal venous plasma ET-1 concentrations in DOCA-salt and sham rats. The magnitude of that increase was roughly twice than that in rats with ETB receptor blockade alone. This suggests that a significant amount of ET-1 is removed from the circulation by ETA receptor binding and is consistent with a previous hypothesis (13) that functional ETA receptors also act as "clearance" receptors. There was, however, no significant difference in the estimated amount of ET-1 bound to ETA receptors in the splanchnic vasculature of DOCA-salt and sham rats. This provides further evidence that the production and release of ET-1 are not increased in the splanchnic vasculature of DOCA-salt rats.

Anesthetized vs. conscious rats. Our preliminary studies were performed on anesthetized rats after acute surgery for catheter implantation. The MAP differences between DOCA-salt and sham rats were much less when they were anesthetized than when they were conscious (probably reflecting the important role of the sympathetic nervous system in regulation of blood pressure in DOCA-salt hypertension). Further studies were then performed on conscious rats to avoid the effects of surgery and anesthesia on sympathetic activity, body fluid status, and hormone synthesis or release. Rats also were in a normal crouched posture, instead of lying on their back, when blood was sampled. This is a potentially significant factor when vascular capacitance function is considered. We saw significantly lower plasma ET-1 concentration and nNHSR of ET-1 in conscious rats, presumably reflecting fewer stress- or anesthesia-induced effects on ET-1 formation, metabolism, or uptake. Furthermore, the change in aortic plasma ET-1 level and in nNHSR of ET-1 after ETB receptor blockade was greater in conscious than in anesthetized rats. This indicates that ETB receptor-mediated clearance of ET-1 was decreased in anesthetized and surgically prepared rats. The decreased uptake activity of ETB receptors in anesthetized rats may be due to desensitization of endothelial ETB receptors caused by higher circulating ET-1 level or to a lower cardiac output (and tissue blood flow) under anesthesia. Comparing data from conscious sham and DOCA-salt rats, however, we found consistent evidence that the uptake activity of endothelial ETB receptors in DOCA-salt rats is impaired in the splanchnic vasculature but remains unchanged in the whole body.

Perspectives

The studies reported here show that neither ET-1 content of venous capacitance vessels nor portal venous plasma ET-1 concentration is higher in DOCA-salt than in sham rats. Furthermore, estimated nNHSR of ET-1 is not higher in DOCA-salt than in sham rats, even when major processes removing ET-1 from the circulation are blocked. Collectively, the results provide strong evidence that higher endothelial cell formation of ET-1 is not likely responsible for enhanced ET-1-mediated splanchnic venoconstriction in vivo. When combined with the fact that venous smooth muscle contractile responsiveness to ET-1 is not increased in DOCA-salt rats, the data suggest that the ability of ET receptor antagonists to reduce venomotor tone in DOCA-salt rats in vivo results from actions of the drugs on a nonvascular target. We speculate that the enhanced venoconstrictor effect of ET-1 could be mediated by an action of ET-1 on the sympathetic nervous system. A number of studies have shown prejunctional modulation of sympathetic neurotransmission by ET-1 in vitro (24); e.g., intrarenal arterial infusion of ET-1 inhibited norepinephrine release induced by renal sympathetic nerve stimulation in anesthetized dogs (23). This neuroinhibitory effect of ET-1 was mediated through activation of ETB receptor mechanisms (37). Localization of ET-1 receptors on the nerve terminals has also been reported (11). Neurotransmission in sympathetic ganglia also can be modulated by ET-1 (39). A previous study in our laboratory (16) found that pretreatment of DOCA-salt rats with an ETB receptor antagonist produced greater declines in MCFP after ganglionic blockade than after ganglionic blockade alone. These findings suggest that ET-1 acting at ETB receptors may provide an important contribution to venomotor tone through modulation of sympathetic tone to the veins. The ETB antagonist may have facilitated norepinephrine release from sympathetic nerve terminals on veins, accounting for the significantly larger response of MCFP to subsequent ganglion blockade. This action presumably was more prominent in DOCA-salt rats because of their higher pretreatment levels of endogenous vascular ET-1. The decrease in venous capacitance, previously demonstrated in essential hypertension in humans (22), might be mediated by other mechanisms, such as changes in venous wall structure or other influences on venous smooth muscle activity besides ET-1 and sympathetic input, such as reactive oxygen species.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This work was supported by American Heart Association Mid-West Affiliate Grant 0310077Z and National Heart, Lung, and Blood Institute Grants RO1 HL-63973 and PO1 HL-70687.


   FOOTNOTES
 

Address for reprint requests and other correspondence: G. D. Fink, Dept. of Pharmacology and Toxicology, B440 Life Science Bldg., Michigan State Univ., East Lansing, MI 48824 (E-mail: finkg{at}msu.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Aneman A, Eisenhofer G, Olbe L, Dalenback J, Nitescu P, Fandriks L, and Friberg P. Sympathetic discharge to mesenteric organs and the liver. J Clin Invest 97: 1640–1646, 1996.[ISI][Medline]
  2. Bremnes T, Paasche JD, Mehlum A, Sandberg C, Bremnes B, and Attramadal H. Regulation and intracellular trafficking pathways of the endothelin receptors. J Biol Chem 275: 17596–17604, 2000.[Abstract/Free Full Text]
  3. Burkhardt M, Barton M, and Shaw SG. Receptor- and non-receptor-mediated clearance of big-endothelin and endothelin-1: differential effects of acute and chronic ETA receptor blockade. J Hypertens 18: 273–279, 2000.[CrossRef][ISI][Medline]
  4. Chun M, Lin HY, Henist YI, and Lodish HF. Endothelin-induced endocytosis of cell surface ETA receptors. J Biol Chem 270: 10855–10860, 1995.[Abstract/Free Full Text]
  5. Clozel M. Endothelin sensitivity and receptor binding in the aorta of spontaneously hypertensive rats. J Hypertens 7: 913–917, 1989.[CrossRef][ISI][Medline]
  6. Coker RH, Krishna MG, Lacy DB, Allen EJ, and Wasserman DH. Sympathetic drive to liver and non-hepatic splanchnic tissue during heavy exercise. J Appl Physiol 82: 1244–1249, 1997.[Abstract/Free Full Text]
  7. Davenport AP, Ashby MJ, Easton P, Ella S, Bedford J, Dickerson C, Nunez DJ, Capper SJ, and Brown MJ. A sensitive radioimmunoassay measuring endothelin immuoreactivity in human plasma: comparison of levels in patients with essential hypertension and sham control subjects. Clin Sci Lond 78: 261–264, 1990.[Medline]
  8. Day R, Lariviere R, and Schiffrin EL. In situ hybridization shows increased endothelin-1 mRNA levels in endothelial cells of blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Am J Hypertens 8: 294–300, 1995.[CrossRef][ISI][Medline]
  9. Dupuis J, Schwab AJ, Simard A, Vernacek P, Stewart DJ, and Goresky CA. Kinetics of endothelin-1 binding in the dog liver microcirculation in vivo. Am J Physiol Gastrointest Liver Physiol 277: G905–G914, 1999.[Abstract/Free Full Text]
  10. Dupuis J, Stewart DJ, Cernacek P, and Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 94: 1578–1584, 1996.[Abstract/Free Full Text]
  11. Fernandes LB, Henry PJ, Spalding LJ, Cody SH, Pudney CJ, and Goldie RG. Immunocytochemical detection of endothelin receptors in rat cultured airway nerves. J Cardiovasc Pharmacol 31 Suppl 1: S222–S224, 1998.[CrossRef]
  12. Fink GD, Johnson RJ, and Galligan JJ. Mechanisms of increased venous smooth muscle tone in desoxycorticosterone acetate-salt hypertension. Hypertension 35: 464–469, 2000.[Abstract/Free Full Text]
  13. Frelin C and Guedin D. Why are circulating concentrations of endothelin-1 so low? Cardiovasc Res 28: 1613–1622, 1994.[Free Full Text]
  14. Huang M, Hester RL, Coleman TG, Smith MJ, and Guyton AC. Development of hypertension in animals with reduced total peripheral resistance. Hypertension 20: 828–833, 1992.[Abstract/Free Full Text]
  15. Johnson RJ, Fink GD, Watts SW, and Galligan JJ. Endothelin receptor function in mesenteric veins from deoxycorticosterone acetate salt-hypertensive rats. J Hypertens 20: 665–676, 2002.[CrossRef][ISI][Medline]
  16. Johnson RJ, Galligan JJ, and Fink GD. Effect of an ETB-selective and a mixed ETA/B endothelin receptor antagonist on venomotor tone in deoxycorticosterone-salt hypertension. J Hypertens 19: 431–440, 2001.[CrossRef][ISI][Medline]
  17. Kohno M, Murakawa K, Horio T, Yokokawa K, Yasunari K, Fukui T, and Takeda T. Plasma immunoreactive endothelin-1 in experimental malignant hypertension. Hypertension 18: 93–100, 1991.[Abstract/Free Full Text]
  18. Kohno M, Yasumari K, Murakawa K, Yokokawa k Horio T, Fukui T, and Takeda T. Plasma immunoreactive endothelin in essential hypertension. Am J Med 88: 614–618, 1990.[CrossRef][ISI][Medline]
  19. Lariviere R, Day R, and Schiffrin EL. Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 21: 916–920, 1993.[Abstract/Free Full Text]
  20. Lariviere R, Thibault G, and Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension 21: 294–300, 1993.[Abstract/Free Full Text]
  21. Luscher TF and Vanhoutte PM. Endothelium-dependent responses in human blood vessels. Trends Pharmacol Sci 9: 181–184, 1988.[CrossRef][Medline]
  22. Mark AL. Structural changes in resistance and capacitance vessels in borderline hypertension. Hypertension 6: III69–III73, 1984.[Medline]
  23. Matsuo G, Matsumura Y, Tadano K, and Morimoto S. Effects of sarafotoxin S6c on antidiuresis and norepinephrine overflow induced by stimulation of renal nerves in anesthetized dogs. J Pharmacol Exp Ther 280: 905–910, 1997.[Abstract/Free Full Text]
  24. Mutafova-Yambolieva VN, and Westfall DP. Inhibitory and facilitatory presynaptic effects of endothelin on sympathetic cotransmission in the rat isolated tail artery. Br J Pharmacol 123: 136–142, 1998.[CrossRef][ISI][Medline]
  25. Naruse M, Takagi S, Tanabe A, Naruse K, Adachi C, Yoshimoto T, Seki T, and Takano K. Augmented expression of tissue endothelin-1 messenger RNA is a common feature in hypertensive rats. J Cardiovasc Pharmacol 36 Suppl 1: S195–S197, 2000.
  26. Nguyen PV, Parent A, Deng LY, Fluckiger JP, Thibault G, and Schiffrin EL. Endothelin vascular receptors and responses in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 19: II98–II104, 1992.[Medline]
  27. Nyhof RA, Laine GA, Meininger GA, and Granger HJ. Splanchnic circulation in hypertension. Fed Proc 42: 1690–1693, 1983.[ISI][Medline]
  28. Rickstein SE, Yao T, and Thoren P. Peripheral and central vascular compliances in conscious normotensive and spontaneously hypertensive rats. Acta Physiol Scand 112: 169–177, 1981.[ISI][Medline]
  29. Rubanyi GM and Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol Rev 46: 325–415, 1994.[ISI][Medline]
  30. Safar SE and London GM. Arterial and venous compliance in sustained essential hypertension. Hypertension 10: 133–139, 1987.[Abstract/Free Full Text]
  31. Schiffrin EL. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension 25: 1135–1145, 1995.[Abstract/Free Full Text]
  32. Schiffrin EL, Lariviere R, Li JS, and Sventek P. Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: correlation with vascular structure. J Vasc Res 33: 235–248, 1996.[ISI][Medline]
  33. Schobel HP, Schmeider RE, Gatzka CD, and Messerli FH. A centripetal shift in intravascular volume triggers the onset of early cardiac adaptation in hypertension. J Hypertension 11 Suppl V: S94–S95, 1993.
  34. Shiba R, Yanagisawa M, Miyauchi T, Ishii Y, Kimura S, Uchiyama Y, Masaki T, and Goto K. Elimination of intravenously injected endothelin-1 from the circulation of the rat. J Cardiovasc Pharmacol 13 Suppl 5: S98–S101, 1989.
  35. Sirvio ML, Metsarinne K, Saijomaa O, and Fyhrquist F. Tissue distribution and half-life of 125I-endothelin in the rat: importance of pulmonary clearance. Biochem Biophys Res Commun 167: 1191–1195, 1990.[CrossRef][ISI][Medline]
  36. Suzuki N, Miyauchi T, Tomobe Y, Matsumoto H, Goto K, Masaki T, and Fujino M. Plasma concentrations of endothelin-1 in spontaneously hypertensive rats and DOCA-salt hypertensive rats. Biochem Biophys Res Commun 167: 941–947, 1990.[CrossRef][ISI][Medline]
  37. Suzuki Y, Matsumura Y, Umekawa T, Hayashi K, Takaoka M, and Morimoto S. Effects of endothelin-1 on antidiuresis and norepinephrine overflow induced by stimulation of renal nerves in anesthetized dogs. J Cardiovasc Pharmacol 19: 905–910, 1992.[ISI][Medline]
  38. Takasuka T, Adachi M, Miyamoto C, Furuichi Y, and Watanabe T. Characterization of endothelin receptors ETA and ETB expressed in COS cells. J Biochem (Tokyo) 112: 396–400, 1992.[Abstract/Free Full Text]
  39. Tsutsumi S, Kushiku K, Kuwahara T, Tokunaga R, and Furukawa T. Ionotropic mechanisms involved in postsynaptic inhibition by the endothelins of ganglionic transmission in dog cardiac sympathetic ganglia. J Cardiovasc Pharmacol 26: 707–713, 1995.[ISI][Medline]
  40. Vemulapalli S, Chiu PJ, Rivelli M, Foster CJ, and Sybertz EJ. Modulation of circulating endothelin levels in hypertension and endotoxemia in rats. J Cardiovasc Pharmacol 18: 895–903, 1991.[ISI][Medline]
  41. Watts SW, Fink GD, Northcott CA, and Galligan JJ. Endothelin-1-induced venous contraction is maintained in DOCA-salt hypertension: studies with receptor agonists. Br J Pharmacol 137: 69–79, 2002.[CrossRef][ISI][Medline]
  42. Wessale JL, Adler AL, Novosad EI, Calzadilla SV, Dayton BD, Marsh KC, Winn M, Jae HS, Geldern TWV, Opgenorth TJ, and Wu-Wong JR. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies. Clin Sci Lond 103 Suppl 48: 1125–1175, 2002.
  43. Yamamoto J, Yamane Y, Umeda Y, Yoshioka T, Nakai M, and Ikeda M. Cardiovascular hemodynamics and vasopressin blockade in DOCA-salt hypertensive rats. Hypertension 6: 397–407, 1984.[Abstract/Free Full Text]
  44. Yu M, Gopalakrishnan V, and McNeill JR. Role of endothelin and vasopressin in DOCA-salt hypertension. Br J Pharmacol 132: 1447–1454, 2001.[CrossRef][ISI][Medline]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
E. C. Viel, K. Benkirane, D. Javeshghani, R. M. Touyz, and E. L. Schiffrin
Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats
Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H281 - H288.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
G. Fink, M. Li, Y. Lau, J. Osborn, and S. Watts
Chronic Activation of Endothelin B Receptors: New Model of Experimental Hypertension
Hypertension, September 1, 2007; 50(3): 512 - 518.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/2/H729    most recent
00388.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, H.
Right arrow Articles by Fink, G. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, H.
Right arrow Articles by Fink, G. D.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.